Peripheral arterial disease: A literature review

British Medical Bulletin

Volumn 104, Issue 1, 2012, Pages 21-39

  Abdulhannan, P ^a   Russell, D A ^a   Homer Vanniasinkam, S ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

atherectomy; atherosclerosis; bypass surgery; peripheral arterial disease; revascularization

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HOMOCYSTEINE; NITINOL; PACLITAXEL;

AMPUTATION; ANAMNESIS; ANGIOGENESIS; ATHERECTOMY; ATHEROSCLEROSIS; BLOOD EXAMINATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG ELUTING STENT; ENDOVASCULAR SURGERY; GENE THERAPY; GLYCEMIC CONTROL; GRAFT PATENCY; HUMAN; HYPERTENSION; KINESIOTHERAPY; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LIMB ISCHEMIA; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVASCULARIZATION; REVIEW; SMOKING CESSATION; STENT; TISSUE ENGINEERING; ULTRASOUND;

ATHERECTOMY; CORONARY ARTERY BYPASS; HUMANS; MYOCARDIAL REVASCULARIZATION; PERIPHERAL VASCULAR DISEASES; RISK FACTORS;

EID: 84871252446     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/lds027     Document Type: Review

References (69)

1. Office for National Statistics. Statistical bulletin: births and deaths in England and Wales 2010. http://www.ons.gov.uk/ons/rel/vsob1/death-reg-sum- tables/2010/birthanddeathstatsbull201-tcm77-227848[1].pdf (9 March 2012, date last accessed).
2. Schirmang TC, Ahn SH, Murphy TP et al. Peripheral arterial disease: update of overview and treatment. Med Health R I 2009;92:398-402.
3. Hills AJ, Shalhoub J, Shepherd AC et al. Peripheral arterial disease. Br J Hosp Med 2009;70:560-5.
4. Norgren L, Hiatt WR, Dormandy JA et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007;45(Suppl. S):S5-67.
5. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43.
6. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. NEJM 2001;344:1608-21.
7. Fowkes FG, Housley E, Cawood EH et al. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384-92.
8. Flu HC, Tamsma JT, Lindeman JHN et al. A systematic review of implementation of established recommended secondary prevention measures in patients with PAOD. Eur J Vasc Endovasc Surg 2010;39:70-86.
9. Faxon DP, Fuster V, Libby P et al. Atherosclerotic vascular disease conference: Writing Group III: pathophysiology. Circulation 2004;109:2617-25.
10. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
11. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
12. Bartholomew JR, Olin JW. Pathophysiology of peripheral arterial disease and risk factors for its development. Cleve Clin J Med 2006;73(Suppl. 4):S8-14.
13. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 2006;113:e463-654.
14. Rothwell PM, Eliasziw M, Gutnikov SA et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004;363:915-24.
15. Cole SEA, Walker RA, Norris R. Vascular Laboratory Practice IPEM Part III. York: Institute of Physics and Engineering in Medicine, 2001.
16. Ubbink DT. Toe blood pressure measurements in patients suspected in leg ischaemia: a new laser Doppler device compared with photo-plethysmography. Eur J Vasc Endovasc Surg 2004;27:629-34.
17. Marston WA, Davies SW, Armstrong B et al. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularisation. J Vasc Surg 2006;44:108-14.
18. Resnick HE, Lindsay RS, McDermott MM et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the strong heart study. Circulation 2004;109:733-9.
19. Becker F, Robert-Ebadi H, Ricco J-B et al. Management of critical limb ischaemia and diabetic foot. Clinical practice guidelines of the European Society for Vascular Surgery. Chapter 1: definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg 2011;42(S2):S4-12.
20. Earnshaw JJ, Gaines PA, Beard JD. Management of acute lower limb ischaemia. In Beard JD, Gaines PA (eds). A Companion to Specialist Surgical Practice. Vascular and Endovascular Surgery, 3rd edn. London: Elsevier Saunders Publishers, 2006, pp. 157-73.
21. Berridge D, Kessel D, Robertson I. Surgery versus thrombolysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev 2009;(2). doi: 10.1002/14651858.
22. Catalano C, Fraioli F, Laghi A et al. Infrarenal aortic and lower-extremity arterial disease: diagnostic performance of multi-detector row CT angiography. Radiology 2004;231: 555-63.
23. Ouwendijk R, De Vries M, Pattynama PM et al. Imaging peripheral arterial disease: a randomised controlled trial comparing contrast-enhanced MR angiography and multi-detector row CT angiography. Radiology 2005;236:1094-103.
24. NICE Clinical Guidelines. Lower limb peripheral arterial disease: diagnosis and management. Issued August 2012. http://publications.nice.org.uk/ lower-limb-peripheral-arterial-diseasediagnosis-and-management-cg147/ guidance#imaging-for-revascularisation.
25. Sadowski EA, Bennett LK, Chan MR et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-57.
26. Sritharan K, Davies AH. The ischaemic leg. Br J Hosp Med (Lond) 2006;67:M56-58.
27. Waybill M, Waybill P. Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interv Radiol 2001;12:3-9.
28. Hawkins IF, Cho KJ, Caridi JG. Carbon dioxide in angiography to reduce the risk of contrast-induced nephropathy. Radiol Clin North Am 2009;47:813-25.
29. Aspelin P, Aubry P, Fransson S-G et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-9.
30. Watson L, Ellis B, Leng GC. Exercise for intermittent claudication (Review). Cochrane Database Syst Rev 2008;(4). doi: 10.1002/14651858.
31. Rowlands TE, Donnelly R. Medical therapy for intermittent claudication (review). Eur J Vasc Endovasc Surg 2007;34:314-21.
32. Shalhoub J, Qureshi M, Davies A. Supervised exercise in intermittent claudication: a sedentary notion? Vascular 2009;17:66-73.
33. Mazari FAK, Khan JA, Carradice D et al. Randomized clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined treatment for intermittent claudication due to femoropopliteal arterial disease. Br J Surg 2012;99:39-48.
34. Meade T, Zuhrie R, Cook C et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002;325:1139.
35. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. Joint British societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl. 5):v1-52.
36. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
37. European Society of Hypertension-European Society of Cardiology (ESH-ESC) guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
38. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
39. Shahin Y, Mazari F, Chetter I. Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials. Int J Surg 2011;9:209-13.
40. Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 2007;3:229-34.
41. Bhatt DL, Fox KA, Hacke W et al., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events (CHARISMA) trial. N Engl J Med 2006;354:1706-17.
42. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007;357:217-27.
43. Squires H, Simpson E, Meng Y et al. A systematic review and economic evaluation of Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess 2011;15(No. 40):1-210.
44. NICE technology appraisal guidance 223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. www.nice.org.uk/guidance/TA223.
45. Hiatt W, Regensteiner J, Creager M et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001;110:616-22.
46. Loosemore TM, Chalmers TC, Dormandy JA. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int Angiol 1994;13:133-42.
47. Thomas SM, Nassef A. Treatment of chronic lower limb ischaemia. In: Beard JD, Gaines PA (eds). A Companion to Specialist Surgical Practice. Vascular and Endovascular Surgery, 3rd edn. London: Elsevier Saunders Publishers, 2006, pp. 35-68.
48. Muradin G, Bosch J, Stijnen T et al. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta analysis. Radiology 2001;221:137-45.
49. Krankenberg H, Schluter M, Steinkamp HJ et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation 2007;116:285-92.
50. Schillinger M, Sabeti S, Dick P et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007;115: 2745-9.
51. Martens JM, Knippenberg B, Vos J-A et al. Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Vasc Surg 2009;50:687-9.
52. Laird JR, Katzen BT, Scheinert D et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther 2012;19:1-9.
53. Duda SH, Bosiers M, Lammer J et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO Trial. J Endovasc Ther 2006;13:701-10.
54. Dake MD, Ansel GM, Jaff MR et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011;4:495-504.
55. McQuade K, Gable D, Hohman S et al. Randomized comparison of ePTFE/nitinol selfexpanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. J Vasc Surg 2009;49:109-16.
56. Shrikhande GV, McKinsey JF. Use and abuse of atherectomy: where should it be used? Semin Vasc Surg 2008;21:204-9.
57. Garcia LA, Lyden SP. Atherectomy for infrainguinal peripheral artery disease. J Endovasc Ther 2009;16(Suppl. II):II105-15.
58. Shammas NW, Coiner D, Shammas GA et al. Percutaneous lower-extremity arterial interventions with primary balloon angioplasty versus silverhawk atherectomy and adjunctive balloon angioplasty: randomised trial. J Vasc Interv Radiol 2011;22:1223-8.
59. Garnic JD, Hurwitz AS. Endovascular excimer laser atherectomy techniques to treat complex peripheral vascular disease: an orderly process. Tech Vasc Interv Radiol 2005;8:150-9.
60. NICE Interventional Procedure Guidance 380: percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. www.nice/guidance/IPG380.
61. Klinkert P, Schepers A, Burger DH et al. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomised controlled trial. J Vasc Surg 2003;37:149-55.
62. Murie JA. Arterial disorders. In: Williams N, Bulstrode C, O'Connell PR (eds). Bailey and Love's Short Practice of Surgery, 25th edn. London: Edward Arnold, 2008, pp. 899-924.
63. Devine C, Hons B, McCollum C. Heparin-bonded Dacron of polytetrafluoroethylene for femoropopliteal bypass grafting: a multicenter trial. J Vasc Surg 2001;33:533-9.
64. Lindholt J, Gottschalksen B, Johannesen N et al. The Scandinavian Propatenw Trial-1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses-a randomised clinical controlled multi-centre trial. Eur J Vasc Endovasc Surg 2011;41:668-73.
65. Earnshaw JJ. The current role of rifampicin-impregnated grafts: pragmatism versus science. Eur J Vasc Endovasc Surg 2000;20:409-12.
66. Adam DJ, Beard JD, Cleveland T et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre randomised controlled trial. Lancet 2005;366:1925-34.
67. Datta D, Atkinson G. Rehabilitation and prosthetic developments. In: Beard JD, Gaines PA (eds). Vascular and Endovascular Surgery, 4th edn. Elsevier: Edinburgh, 2009, pp. 97-109.
68. Schmieder GC, Carroll M, Panneton JM. Poor outcomes with cryoplasty for lower extremity arterial occlusive disease. J Vasc Surg 2010;52:362-8.
69. Mughal NA, Russell DA, Ponnambalam V et al. Gene therapy in the treatment of peripheral arterial disease. Br J Surg 2012;99:6-15.